RxDoctor Payments Data

Omar Khatib, MD

Interventional Cardiology · Cleveland, OHNPI 1235306507

Payments from drug & device makers

$835in general payments, 2019–2025

Across 22 payments — averaging $37.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$336
  • Edwards Lifesciences$132
  • Pfizer$97
  • Boston Scientific$59
  • Novartis$51
  • Altathera Pharmaceuticals LLC$42
  • plus $117 from 5 others

What the payments were for

  • Food & beverage$835100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$835 in reported general payments places this provider in the 15th percentile of 256 interventional cardiology providers in Ohio.

See all interventional cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$125,811
Medicare patients
600
Services billed
1,744

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban481$489,975
EntrestoSacubitril/Valsartan141$166,590
XareltoRivaroxaban103$103,548
BrilintaTicagrelor97$71,759
Repatha SureclickEvolocumab22$34,879
JardianceEmpagliflozin13$13,284
Metoprolol Succinate571$8,115
Ranolazine ErRanolazine66$7,221
Atorvastatin Calcium561$5,177
Carvedilol496$4,293
ClopidogrelClopidogrel Bisulfate326$3,823
Telmisartan155$3,246
Rosuvastatin Calcium223$3,086
Valsartan59$3,003
Amlodipine Besylate380$2,395

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$97$489,975481 claims
NovartisEntresto$51$166,590141 claims
Johnson & JohnsonXarelto$33$103,548103 claims
AstraZenecaBrilinta$20$71,75997 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 256 interventional cardiology providers in Ohio.

Other interventional cardiology in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →